AIMS: Left ventricular assist device (LVAD) therapy improves the haemodynamics of advanced heart failure patients. However, it is unknown whether haemodynamic optimization improves haemocompatibility-related adverse events (HRAEs). This study aimed to assess HRAEs in patients with optimized haemodynamics. METHODS AND RESULTS: Eighty-three outpatients [aged 61 (53-67) years, 50 male] underwent a haemodynamic ramp test at 253 (95-652) days after LVAD implantation, and 51 (61%) had optimized haemodynamics (defined as central venous pressure < 12 mmHg, pulmonary artery wedge pressure < 18 mmHg, cardiac index > 2.2 L/min/m2 ) following LVAD speed adjustment. One-year survival free of any HRAEs (non-surgical bleeding, thromboembolic event, pump thrombosis, or neurological event) was achieved in 75% of the optimized group and in 44% of the non-optimized group (hazard ratio 0.36, 95% confidence interval 0.18-0.73, P = 0.003). The net haemocompatibility score, using four escalating tiers of hierarchal severity to derive a total score for events, was significantly lower in the optimized group than the non-optimized group (1.02 vs. 2.00 points/patient; incidence rate ratio 0.51, 95% confidence interval 0.29-0.90, P = 0.021). CONCLUSION: Left ventricular assist device patients in whom haemodynamics can be optimized had greater freedom from HRAEs compared to those without optimized haemodynamics.
AIMS: Left ventricular assist device (LVAD) therapy improves the haemodynamics of advanced heart failure patients. However, it is unknown whether haemodynamic optimization improves haemocompatibility-related adverse events (HRAEs). This study aimed to assess HRAEs in patients with optimized haemodynamics. METHODS AND RESULTS: Eighty-three outpatients [aged 61 (53-67) years, 50 male] underwent a haemodynamic ramp test at 253 (95-652) days after LVAD implantation, and 51 (61%) had optimized haemodynamics (defined as central venous pressure < 12 mmHg, pulmonary artery wedge pressure < 18 mmHg, cardiac index > 2.2 L/min/m2 ) following LVAD speed adjustment. One-year survival free of any HRAEs (non-surgical bleeding, thromboembolic event, pump thrombosis, or neurological event) was achieved in 75% of the optimized group and in 44% of the non-optimized group (hazard ratio 0.36, 95% confidence interval 0.18-0.73, P = 0.003). The net haemocompatibility score, using four escalating tiers of hierarchal severity to derive a total score for events, was significantly lower in the optimized group than the non-optimized group (1.02 vs. 2.00 points/patient; incidence rate ratio 0.51, 95% confidence interval 0.29-0.90, P = 0.021). CONCLUSION: Left ventricular assist device patients in whom haemodynamics can be optimized had greater freedom from HRAEs compared to those without optimized haemodynamics.
Authors: James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: James K Kirklin; David C Naftel; Francis D Pagani; Robert L Kormos; Susan Myers; Michael A Acker; Joseph Rogers; Mark S Slaughter; Lynne W Stevenson Journal: J Heart Lung Transplant Date: 2015-12 Impact factor: 10.247
Authors: Nir Uriel; Paolo C Colombo; Joseph C Cleveland; James W Long; Christopher Salerno; Daniel J Goldstein; Chetan B Patel; Gregory A Ewald; Antone J Tatooles; Scott C Silvestry; Ranjit John; Christiano Caldeira; Valluvan Jeevanandam; Andrew J Boyle; Kartik S Sundareswaran; Poornima Sood; Mandeep R Mehra Journal: Circulation Date: 2017-04-06 Impact factor: 29.690
Authors: Christopher T Sparrow; Michael E Nassif; David S Raymer; Eric Novak; Shane J LaRue; Joel D Schilling Journal: JACC Heart Fail Date: 2015-11-11 Impact factor: 12.035
Authors: Nir Uriel; Gabriel Sayer; Karima Addetia; Savitri Fedson; Gene H Kim; Daniel Rodgers; Eric Kruse; Keith Collins; Sirtaz Adatya; Nitasha Sarswat; Ulrich P Jorde; Colleen Juricek; Takeyoshi Ota; Valluvan Jeevanandam; Daniel Burkhoff; Roberto M Lang Journal: JACC Heart Fail Date: 2015-12-30 Impact factor: 12.035